Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?
- 9 Downloads
Indications and advantages of parathyroidectomy in patients with normocalcemic primary hyperparathyroidism (NHPT) are still matter of debate. We aimed to compare clinical presentation and surgical outcome between normocalcemic and hypercalcemic forms in a consecutive series of patients who underwent parathyroidectomy for primary hyperparathyroidism.
Data of 731 consecutive patients were reviewed and retrospectively compared according to normocalcemic (group A) and hypercalcemic (group B) phenotypes.
No significant differences were found between the two groups concerning demographics and symptomatic onset. Mean preoperative PTH levels were significantly higher in group B (252.0 ± 320.7 pg/ml vs 151.7 ± 112.0; p < 0.001). Mean PTH levels in first postoperative day were significantly lower in group B (30.9 ± 26.2 vs 22.7 ± 20.7; p < 0.001). No significant difference in overall accuracy of preoperative imaging studies was found. Significantly more patients in group A underwent bilateral explorations (83 vs 255; p < 0.05). The rate of multigland disease was significantly higher in group A (13.0 vs 6.8%; p < 0.05). At a mean follow-up period of 72.9 ± 46.8 months, all but three patients, among the 96 of group A who completed follow-up evaluation, were biochemically cured. The remaining patients had persistent high PTH values. Among NHPT patients who had target organ disease before parathyroidectomy, improvement in bone density and in kidney stones was observed in 41.7 and 40.0%, and stability in 50.0 and 60.0% respectively.
In normocalcemic patients, parathyroidectomy is as safe and effective as in hypercalcemic patients. In the presence of symptoms and/or target organ disease, parathyroidectomy may have a positive effect on the outcome of NHPT patients.
KeywordsHyperparathyroidism Normocalcemic Parathyroidectomy Outcome
Study conception and design: E Traini, M Raffaelli, CP Lombardi, and R Bellantone. Acquisition of the data: SE Tempera and S Russo. Analysis and interpretation of data: E Traini, M Raffaelli, C De Crea, and SE Tempera. Drafting of manuscript: E Traini, M Raffaelli, SE Tempera, and S Russo. Critical revision of manuscript: R Bellantone, CP Lombardi, and C De Crea.
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Kontogeorgos G, Trimpou P, Laine CM, Olerod G, Lindahl A, Landin-Wilhelmsen K (2015) Normocalcaemic, vitamin D-sufficient hyperparathyroidism - high prevalence and low morbidity in the general population: a long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden. Clin Endocrinol 83(2):277–284. https://doi.org/10.1111/cen.12819 CrossRefGoogle Scholar
- 6.Berger C, Almohareb O, Langsetmo L, Hanley DA, Kovacs CS, Josse RG, Adachi JD, Prior JC, Towheed T, Davison KS, Kaiser SM, Brown JP, Goltzman D (2015) Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. Clin Endocrinol 82(3):359–368. https://doi.org/10.1111/cen.12569 CrossRefGoogle Scholar
- 8.Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, Doherty GM, Herrera MF, Pasieka JL, Perrier ND, Silverberg SJ, Solorzano CC, Sturgeon C, Tublin ME, Udelsman R, Carty SE (2016) The American Association of Endocrine Surgeons Guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 151(10):959–968. https://doi.org/10.1001/jamasurg.2016.2310 CrossRefPubMedGoogle Scholar
- 9.Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3561–3569. https://doi.org/10.1210/jc.2014-1413 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D'Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr, Brandi ML, Bilezikian JP (2017) Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 28(1):1–19. https://doi.org/10.1007/s00198-016-3716-2 CrossRefPubMedGoogle Scholar
- 11.Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E, Borderie D, Kahan A, Cormier C (2013) Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 98(8):3213–3220. https://doi.org/10.1210/jc.2013-1518 CrossRefPubMedGoogle Scholar
- 15.Lombardi CP, Raffaelli M, Traini E, Di Stasio E, Carrozza C, De Crea C, Zuppi C, Bellantone R (2008) Intraoperative PTH monitoring during parathyroidectomy: the need for stricter criteria to detect multiglandular disease. Langenbeck's Arch Surg 393(5):639–645. https://doi.org/10.1007/s00423-008-0384-5 CrossRefGoogle Scholar
- 16.Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM, Bauer DC, Orwoll ES, Bilezikian JP (2013) Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 98(7):2734–2741. https://doi.org/10.1210/jc.2013-1300 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Marques TF, Vasconcelos R, Diniz E, Rego D, Griz L, Bandeira F (2011) Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? Arq Bras Endocrinol Metabol 55(5):314–317. https://doi.org/10.1590/S0004-27302011000500003 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Berger C, Langsetmo L, Hanley, D, Hadachi J, Kovacs C, Brown J, Josse R, Goltzman D (2011) Relative prevalence of normocalcemic and hypercalcemic hyperparathyroidism in a community-dwelling cohort. Paper presented at the 33rd Annual Meeting of the American Society of Bone and Mineral Research, San Diego, CaliforniaGoogle Scholar
- 24.Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911–1300. https://doi.org/10.1210/jc.2011-0385 CrossRefPubMedGoogle Scholar
- 26.Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM (1988) Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 67(6):1294–1298. https://doi.org/10.1210/jcem-67-6-1294 CrossRefPubMedGoogle Scholar
- 28.de la Plaza LR, Ramia Ángel JM, Arteaga Peralta V, García Amador C, López Marcano AJ, Medina Velasco AA, González Sierra B, Manuel Vázquez A, Latorre Fragua RA (2017) Elevated parathyroid hormone levels after successful parathyroidectomy for primary hyperparathyroidism: a clinical review. Eur Arch Otorhinolaryngol. https://doi.org/10.1007/s00405-017-4836-9